Tesamorelin

How It Works

The biology, explained.

Your brain and pituitary gland work together to regulate growth hormone.

One of the signals involved is called growth hormone-releasing hormone, or GHRH.

Tesamorelin mimics that signal.

It stimulates your own growth hormone

Rather than supplying growth hormone directly, tesamorelin stimulates the pituitary gland to release it.

Growth hormone influences several processes, including fat metabolism, tissue growth, and the production of another hormone called IGF-1.

What makes visceral fat different?

Not all body fat is stored in the same place.

Subcutaneous fat sits directly beneath your skin. It's the fat you can generally pinch around your waist.

Visceral fat is stored deeper inside your abdomen, around internal organs.

Excess visceral fat is associated with metabolic and cardiovascular health risks.

Clinical trials have shown that tesamorelin can reduce visceral fat in adults with HIV-associated lipodystrophy.

But here's an important distinction: reducing internal abdominal fat doesn't necessarily mean you'll see dramatic changes in the fat covering your abs.

What about muscle?

Because tesamorelin stimulates growth hormone and increases IGF-1, it has attracted interest in bodybuilding and fitness communities.

But that doesn't establish that it builds meaningful amounts of muscle or improves athletic performance in healthy adults.

Go deeper: The science

Tesamorelin is a modified GHRH analog that activates growth hormone-releasing hormone receptors in the pituitary gland.

This stimulates endogenous growth hormone secretion and increases circulating IGF-1.

Growth hormone influences fat breakdown and metabolic signaling.

Its effects depend on an intact hypothalamic-pituitary system.

The Evidence

What do the studies actually show?

Unlike many experimental peptides, tesamorelin has undergone substantial human clinical research.

Visceral fat: The major trials

In two large, randomized clinical trials involving a combined 806 adults with HIV-associated abdominal fat accumulation, researchers compared tesamorelin with placebo.

After 26 weeks, tesamorelin produced a significantly greater reduction in visceral fat.

The combined treatment effect was approximately 15.4% greater visceral-fat reduction than placebo.

Importantly, the trials did not show comparable reductions in the fat directly beneath the skin.

Does the fat come back?

This is an important finding.

In follow-up research, participants who continued treatment generally maintained reductions in visceral fat.

Those who switched to placebo lost much of the benefit.

In other words, the effects weren't necessarily permanent after treatment stopped.

What about liver fat?

Researchers have also investigated tesamorelin's effects on fat accumulation in the liver.

In a randomized study involving 50 adults with HIV-associated abdominal fat accumulation, tesamorelin reduced both visceral fat and liver fat over six months.

A later study involving 61 participants with HIV and fatty liver disease also reported improvements in liver-fat measurements.

These findings are interesting, but tesamorelin is not FDA-approved as a general treatment for fatty liver disease.

Does it cause overall weight loss?

Here's where expectations need adjusting.

Tesamorelin's approved use concerns body-fat distribution, not general weight reduction.

A person can experience reduced visceral fat without seeing a major change on the bathroom scale.

And we shouldn't assume results from people with HIV-associated lipodystrophy will be identical in otherwise healthy individuals.

The takeaway: Tesamorelin has convincing evidence for reducing visceral fat in a specific patient population. Its broader cosmetic, athletic, and longevity benefits remain uncertain.

Risks & Effects

What should people know?

Because tesamorelin influences growth hormone and IGF-1, its safety considerations are different from those of GLP-1 medications.

Known adverse effects

Water retention

Some people experience swelling or puffiness as their bodies retain additional fluid.

Joint and muscle discomfort

Joint pain, muscle aches, and discomfort in the hands or extremities have been reported.

Injection-site reactions

Redness, itching, irritation, pain, and bruising can occur.

Allergic reactions

Hypersensitivity reactions, including rash and hives, have occurred in clinical studies.

Important medical warnings

Elevated IGF-1

Tesamorelin increases IGF-1, a hormone involved in growth and tissue signaling.

The consequences of prolonged IGF-1 elevation aren't fully understood. FDA labeling recommends monitoring IGF-1 during treatment.

Blood sugar changes

Tesamorelin can worsen glucose tolerance and increase the risk of developing diabetes.

That's important because growth hormone can influence how the body responds to insulin.

Cancer-related precautions

Growth hormone is involved in cellular growth.

Tesamorelin is contraindicated in patients with active malignancy. Its prescribing information includes additional precautions for people with a history of cancer.

This does not establish that tesamorelin causes cancer, but it makes the growth-signaling effects medically important.

Pituitary disorders

Tesamorelin depends on the body's growth hormone signaling system and is contraindicated in people with certain disruptions of the hypothalamic-pituitary axis.

Pregnancy

Tesamorelin is contraindicated during pregnancy.

Different products matter

Egrifta SV and Egrifta WR are approved prescription formulations, but they have different product-specific preparation and administration instructions.

They are not interchangeable on a milligram-for-milligram basis.

A research vial marketed as tesamorelin isn't automatically equivalent to either approved product.

Bottom line: Tesamorelin can meaningfully affect visceral fat, but it also changes hormonal signaling and carries important metabolic and safety risks.

Real Experiences

What are people saying?

Tesamorelin has attracted considerable interest in peptide, bodybuilding, and longevity communities.

But one theme keeps appearing: people often expect something different from what tesamorelin was actually studied to do.

The good

Some people describe a smaller waistline or clothing fitting more loosely after several weeks.

Others report subtle changes in their midsection without dramatic overall weight loss.

Some also describe better recovery or changes in sleep, although these effects are not established clinical benefits in healthy users.

The not-so-good

Water retention is a recurring topic.

People describe feeling puffy, noticing tighter rings, experiencing swollen hands, or temporarily seeing the scale move upward.

Others report joint discomfort or injection-site irritation.

The frustrating

Some people say they didn't notice much visible abdominal change.

Others report that changes were slower or less dramatic than expected.

That's particularly understandable when someone expects tesamorelin to eliminate subcutaneous belly fat rather than influence deeper visceral fat.

The complicated

Tesamorelin is sometimes discussed alongside ipamorelin, growth hormone, GLP-1 medications, or other interventions.

When several compounds are involved, it's difficult to determine which one caused a particular result.

And visual changes alone can't tell someone how much visceral fat they've actually lost.

So what should we believe?

Clinical trials demonstrate visceral-fat reduction in the population studied.

Community experiences show how differently those changes may be perceived—and how expectations can shape people's impressions.

The science tells us what tesamorelin can do in studied patients. The stories remind us that visible results and actual biological changes aren't always the same thing.

These summaries reflect real public discussions. Individual anecdotes are unverified and do not establish effectiveness, causation, or how frequently an effect occurs.